These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Polyamine-oligonucleotide conjugates: a promising direction for nucleic acid tools and therapeutics. Menzi M; Lightfoot HL; Hall J Future Med Chem; 2015; 7(13):1733-49. PubMed ID: 26424049 [TBL] [Abstract][Full Text] [Related]
6. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. Juliano RL; Carver K; Cao C; Ming X J Drug Target; 2013 Jan; 21(1):27-43. PubMed ID: 23163768 [TBL] [Abstract][Full Text] [Related]
7. Recent developments in oligonucleotide conjugation. Singh Y; Murat P; Defrancq E Chem Soc Rev; 2010 Jun; 39(6):2054-70. PubMed ID: 20393645 [TBL] [Abstract][Full Text] [Related]
8. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. Nakagawa O; Ming X; Huang L; Juliano RL J Am Chem Soc; 2010 Jul; 132(26):8848-9. PubMed ID: 20550198 [TBL] [Abstract][Full Text] [Related]
10. Developments in siRNA Modification and Ligand Conjugated Delivery To Enhance RNA Interference Ability. Maguregui A; Abe H Chembiochem; 2020 Jul; 21(13):1808-1815. PubMed ID: 32181563 [TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of a splice-switching oligonucleotide by cationic polyplexes of RGD-oligonucleotide conjugate. Ming X; Feng L Mol Pharm; 2012 May; 9(5):1502-10. PubMed ID: 22497548 [TBL] [Abstract][Full Text] [Related]
12. Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Juliano RL; Ming X; Carver K; Laing B Nucleic Acid Ther; 2014 Apr; 24(2):101-13. PubMed ID: 24383421 [TBL] [Abstract][Full Text] [Related]
13. Chemical strategies for the synthesis of peptide-oligonucleotide conjugates. Lu K; Duan QP; Ma L; Zhao DX Bioconjug Chem; 2010 Feb; 21(2):187-202. PubMed ID: 19856957 [TBL] [Abstract][Full Text] [Related]
14. Recent preclinical and clinical advances in oligonucleotide conjugates. Craig K; Abrams M; Amiji M Expert Opin Drug Deliv; 2018 Jun; 15(6):629-640. PubMed ID: 29727206 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Juliano R; Alam MR; Dixit V; Kang H Nucleic Acids Res; 2008 Jul; 36(12):4158-71. PubMed ID: 18558618 [TBL] [Abstract][Full Text] [Related]
16. Chemical Manipulation of the Endosome Trafficking Machinery: Implications for Oligonucleotide Delivery. Juliano RL Biomedicines; 2021 May; 9(5):. PubMed ID: 34063104 [TBL] [Abstract][Full Text] [Related]
17. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. Juliano RL Curr Opin Mol Ther; 2005 Apr; 7(2):132-6. PubMed ID: 15844620 [TBL] [Abstract][Full Text] [Related]
18. Reality check: lipid-oligonucleotide conjugates for therapeutic applications. Goodnow RA Expert Opin Drug Discov; 2023 Feb; 18(2):129-134. PubMed ID: 36546308 [TBL] [Abstract][Full Text] [Related]
19. Conjugation with receptor-targeted histidine-rich peptides enhances the pharmacological effectiveness of antisense oligonucleotides. Nakagawa O; Ming X; Carver K; Juliano R Bioconjug Chem; 2014 Jan; 25(1):165-70. PubMed ID: 24354269 [TBL] [Abstract][Full Text] [Related]